[Neuroprotective potential of pyrimidine-4-H1-OHa derivatives in experimental cerebral ischemia].

Objective: To evaluate the effect of ten pyrimidine-4-H1-OH derivatives on the change in the activity of mitochondrial respiratory chain complexes and tricarboxylic acid cycle enzymes in rats under experimental brain ischemia.

Material And Methods: Cerebral ischemia in rats was modeled by irreversible occlusion of the middle cerebral artery. Two hundred and sixty male Wistar rats were administered studied compounds at a dose of 50 mg/kg (orally) and the reference - L-carnitine at a dose of 200 mg/kg (orally) for 72 hours after ischemia modeling (once a day).

[Carfilzomib, lenalidomide and dexamethasone in relapsed/refractory multiple myeloma patients: the real-life experience].

Background: Carfilzomib, lenalidomide, and dexamethasone (KRd) have been approved for the treatment of relapsed and refractory multiple myeloma (RRMM) based on ASPIRE clinical trial.

Aim: Analysis of efficacy and safety of KRd in routine clinical practice.

Materials And Methods: The prospective analysis included patients with MM who received at least one line of previous therapy.

[Epidemiology of multiple myeloma in city Moscow].

Aim: To study the epidemiology of multiple myeloma in the city of Moscow and compare the results obtained with data from similar studies in other countries.

Materials And Methods: The study is based on information from a database of case histories of 3942 patients suffering from symptomatic MM, residents of the city of Moscow, which is maintained at the Hematologic Moscow City Center of S.P.

Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.

Aim: To analyze the long-term efficacy and safety of ATR in adult patients with primary resistant ITP in real-world clinical practice.

Materials And Methods: The article contains long-term results analysis of ATR application under real clinical practice conditions in 138 patients (40 men and 98 women) whose median age at the beginning of therapy was 59 (18-86) years. Two ATR medicines-romiplostim (100 patients) and eltrombopag (38 patients) were used.

[Molecular targets for searching of endothelial-protective substances].

Endothelial dysfunction underlies the development of many cardiovascular diseases. Thus endothelium becomes an independent therapeutic target, and the search of new substances with endothelial-protective action to date is one of the promising tasks for pharmacotherapy and medicinal chemistry. Molecular modeling is an effective tool for solving this problem.